A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Korean Study Participants With Moderate to Severe Plaque Psoriasis

Summary

The purpose of the study is to evaluate the efficacy and safety of bimekizumab compared with placebo.

Timeline

Start

2021-09-27

Primary completion

2022-09-05

Completion

2022-09-06

Outcome

Met primary endpoint

paper PASI 90: 81.3% vs. 0%; IGA 0/1: 87.5% vs. 0%, p < 0.001 for both). PMID 39328126 ↗

paper At week 16, bimekizumab-treated patients had significantly higher clinical responses versus placebo-treated patients PMID 39328126 ↗

Publications

• Results Youn SW, Jo SJ, Park CJ, Kim DH, Shin BS, Jeong KH, Bang CH, Cross N, Thirlwell J, Hoepken B. Bimekizumab efficacy and safety in Korean patients with moderate to severe plaque psoriasis: A phase 3, randomized, placebo-controlled, double-blinded study. J Dermatol. 2024 Nov;51(11):1392-1403. doi: 10.1111/1346-8138.17446. Epub 2024 Sep 27.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bimekizumab	Monoclonal antibody	—	Subcutaneous

Indications